with Amedisys surviving the Merger as a wholly owned subsidiary of Unite Amedisys stock climbed Friday after the provider of home health care agreed to waive its right to terminate a merger ...
Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, ...
Zacks Investment Research on MSN14d
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to SayFor the quarter ended December 2024, Amedisys (AMED) reported revenue of $598.05 million, up 4.8% over the same period last year. EPS came in at $0.96, compared to $0.94 in the year-ago quarter. The ...
Hosted on MSN28d
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination makes it difficult to conclusively predict that Amedisys will beat the consensus EPS estimate. Does Earnings ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), Amedisys ...
On Monday, Raymond James reaffirmed its Market Perform rating on Amedisys stock, following the company’s fourth-quarter financial results for 2024. Amedisys reported a revenue of $598.1 million ...
On Monday, Raymond (NSE:RYMD) James reaffirmed its Market Perform rating on Amedisys stock, following the company’s fourth-quarter financial results for 2024. Amedisys reported a revenue of $598.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback